XML 47 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Net revenues $ 16,887 $ 18,271 $ 21,853
Cost of sales 9,351 9,975 11,237
Gross profit 7,537 8,296 10,615
Research and development expenses 1,010 1,213 1,778
Selling and marketing expenses 2,614 2,916 3,395
General and administrative expenses 1,192 1,298 1,451
Intangible assets impairments 1,639 1,991 3,238
Goodwill impairment   3,027 [1] 17,100
Other asset impairments, restructuring and other items 423 987 1,836
Legal settlements and loss contingencies 1,178 (1,208) 500
Other income (76) (291) (1,199)
Operating (loss) income (443) (1,637) (17,484)
Financial expenses—net 822 959 895
Income (loss) before income taxes (1,265) (2,596) (18,379)
Income taxes (benefit) (278) (195) (1,933)
Share in (profits) losses of associated companies—net 13 71 3
Net income (loss) (1,000) (2,472) (16,449)
Net loss attributable to non-controlling interests (2) (322) (184)
Net income (loss) attributable to Teva (999) (2,150) (16,265)
Accrued dividends on preferred shares   249 260
Net income (loss) attributable to ordinary shareholders $ (999) $ (2,399) $ (16,525)
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ (0.91) $ (2.35) $ (16.26)
Diluted $ (0.91) $ (2.35) $ (16.26)
Weighted average number of shares (in millions):      
Basic 1,091 1,021 1,016
Diluted 1,091 1,021 1,016
[1] Goodwill impairment mainly attributable to the International Markets segment, Mexico and Medis.